2020
Early access to antiretroviral therapy versus standard of care among HIV‐positive participants in Eswatini in the public health sector: the MaxART stepped‐wedge randomized controlled trial
Khan S, Spiegelman D, Walsh F, Mazibuko S, Pasipamire M, Chai B, Reis R, Mlambo K, Delva W, Khumalo G, Zwane M, Fleming Y, Mafara E, Hettema A, Lejeune C, Chao A, Bärnighausen T, Okello V. Early access to antiretroviral therapy versus standard of care among HIV‐positive participants in Eswatini in the public health sector: the MaxART stepped‐wedge randomized controlled trial. Journal Of The International AIDS Society 2020, 23: e25610. PMID: 32949103, PMCID: PMC7507004, DOI: 10.1002/jia2.25610.Peer-Reviewed Original ResearchConceptsViral suppressionStandard of careAntiretroviral treatmentCox proportional hazards modelHealth systemART-naïve participantsHIV-positive patientsHIV-positive adultsViral load monitoringHIV-positive participantsAppropriate care managementProportional hazards modelEarly accessPublic sector health facilitiesHealth system effectsPublic health systemHealth system's abilityClinic transitionAntiretroviral therapyCD4 countCare retentionVL monitoringPublic health sectorDisease stageEndpoint rateGetting to 90–90–90: Experiences from the MaxART Early Access to ART for All (EAAA) Trial in Eswatini
Walsh F, Khan S, Bärnighausen T, Hettema A, Lejeune C, Mazibuko S, Mlambo CK, Reis R, Fleming Y, Khumalo G, Zwane M, Okello V, Spiegelman D. Getting to 90–90–90: Experiences from the MaxART Early Access to ART for All (EAAA) Trial in Eswatini. Current HIV/AIDS Reports 2020, 17: 324-332. PMID: 32474844, DOI: 10.1007/s11904-020-00501-6.Peer-Reviewed Original ResearchConceptsTreatment guidelinesRoutine viral load monitoringNational HIV careViral load monitoringAdolescent malesSystem-level barriersEarly accessInnovative community-based approachesPublic health systemCommunity outreach strategiesImplementation science researchART initiationHIV careHIV testHIV testingMiddle-income countriesUNAIDS 90Adult menMultiple interventionsHealth systemAdolescent femalesEswatini MinistryTrialsFast trackBaseline data
2012
Elevated alanine aminotransferase in antiretroviral‐naïve HIV‐infected African patients: magnitude and risk factors
Nagu T, Kanyangarara M, Hawkins C, Hertmark E, Chalamila G, Spiegelman D, Mugusi F, Fawzi W. Elevated alanine aminotransferase in antiretroviral‐naïve HIV‐infected African patients: magnitude and risk factors. HIV Medicine 2012, 13: 541-548. PMID: 22416813, PMCID: PMC3391335, DOI: 10.1111/j.1468-1293.2012.01006.x.Peer-Reviewed Original ResearchConceptsElevated alanine aminotransferaseIU/LAlanine aminotransferaseAntiretroviral therapyHigh riskWorld Health Organization clinical stageCD4 T-lymphocyte countFirst-line antiretroviral therapyHepatitis B virus coinfectionALT measurementsLow-density lipoprotein cholesterolLog-binomial regression modelsB virus coinfectionT-lymphocyte countsART-naïve HIVCells/μLHepatotoxic side effectsCurrent tuberculosis (TB) treatmentResource-limited settingsCross-sectional analysisAdvanced immunosuppressionHBV coinfectionART-naïveHIV careLipoprotein cholesterol
2004
Understanding the Role of HIV Load in Determining Weight Change in the Era of Highly Active Antiretroviral Therapy
Mwamburi DM, Wilson IB, Jacobson DL, Spiegelman D, Gorbach SL, Knox TA, Wanke CA. Understanding the Role of HIV Load in Determining Weight Change in the Era of Highly Active Antiretroviral Therapy. Clinical Infectious Diseases 2004, 40: 167-173. PMID: 15614708, DOI: 10.1086/426591.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyVirus loadBody weightAntiretroviral therapyHIV infectionWeight changeStudy visitHuman immunodeficiency virus RNA loadHighly Active Antiretroviral TherapyAbsence of HAARTProspective cohort studyCell count decreaseVirus RNA loadTime of enrollmentStudy intervalRepeated-measures analysisHIV loadHAART useCohort studyRNA loadHAARTPatientsEligible sampleCell countCount decreaseA Randomized Trial of Multivitamin Supplements and HIV Disease Progression and Mortality
Fawzi WW, Msamanga GI, Spiegelman D, Wei R, Kapiga S, Villamor E, Mwakagile D, Mugusi F, Hertzmark E, Essex M, Hunter DJ. A Randomized Trial of Multivitamin Supplements and HIV Disease Progression and Mortality. New England Journal Of Medicine 2004, 351: 23-32. PMID: 15229304, DOI: 10.1056/nejmoa040541.Peer-Reviewed Original ResearchConceptsVitamin AHIV diseaseMultivitamin supplementsHuman immunodeficiency virus (HIV) diseasePlacebo-controlled trialHIV disease progressionStage 4 diseaseLow viral loadHigher CD4Antiretroviral therapyPrimary outcomeImmunodeficiency syndromeRandomized trialsViral loadPregnant womenDisease progressionRelative riskObservational studyDaily supplementCell countEnd pointMicronutrient statusMultivitaminsDiseaseProgressionEffect of Prenatal Vitamin Supplementation on Lower-Genital Levels of HIV Type 1 and Interleukin Type 1β at 36 Weeks of Gestation
Fawzi W, Msamanga G, Antelman G, Xu C, Hertzmark E, Spiegelman D, Hunter D, Anderson D. Effect of Prenatal Vitamin Supplementation on Lower-Genital Levels of HIV Type 1 and Interleukin Type 1β at 36 Weeks of Gestation. Clinical Infectious Diseases 2004, 38: 716-722. PMID: 14986257, DOI: 10.1086/381673.Peer-Reviewed Original ResearchConceptsHIV-1HIV-1-infected pregnant womenVitamin AHIV-1-infected womenType 1Human immunodeficiency virus type 1Immunodeficiency virus type 1Genital HIV-1Prenatal multivitamin supplementsHIV-1 transmissionCervicovaginal lavage specimensHIV Type 1HIV-1 infectionLower genital tractWeeks of gestationPrenatal vitamin supplementationUse of vitaminsVirus type 1Lack of effectPregnancy outcomesVaginal inflammationViral sheddingVitamin supplementationMultivitamin supplementsPregnant women
2002
Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men
Roubenoff R, Grinspoon S, Skolnik PR, Tchetgen E, Abad L, Spiegelman D, Knox T, Gorbach S. Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men. AJP Endocrinology And Metabolism 2002, 283: e138-e145. PMID: 12067854, DOI: 10.1152/ajpendo.00426.2001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntiretroviral Therapy, Highly ActiveBody CompositionBody WeightCD4 Lymphocyte CountCytokinesEnergy MetabolismFollow-Up StudiesHIV InfectionsHIV Wasting SyndromeHumansInterleukin-1Linear ModelsLongitudinal StudiesMaleMiddle AgedNutritional StatusRestTestosteroneThinnessTumor Necrosis Factor-alphaViral LoadConceptsLBM lossPeripheral blood mononuclear cellsIL-1 beta productionWeight lossActive antiretroviral therapyCohort of patientsSerum free testosteroneBlood mononuclear cellsInadequate dietary intakeOngoing cohort studyCytokine tumor necrosisRole of cytokinesIL-1 betaTNF-alpha productionInterleukin-1 betaMo of observationLean body massKcal/dayAntiretroviral therapyCohort studyFree testosteroneHIV infectionIndependent predictorsCytokine productionMononuclear cellsCorrelates of Plasma HIV-1 RNA Viral Load Among HIV-1 Seropositive Women in Dar es Salaam, Tanzania
Kapiga SH, Bang H, Spiegelman D, Msamanga GI, Coley J, Hunter DJ, Fawzi WW. Correlates of Plasma HIV-1 RNA Viral Load Among HIV-1 Seropositive Women in Dar es Salaam, Tanzania. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2002, 30: 316-323. PMID: 12131569, DOI: 10.1097/01.qai.0000014767.47046.c8.Peer-Reviewed Original ResearchConceptsHIV-1 RNA viral loadRNA viral loadPlasma HIV-1 RNA viral loadViral loadCopies/mLLymphocyte countHIV-1 positive pregnant womenHIV-1-seropositive womenMedian viral loadHigh viral loadPrevention of malariaTime of deliverySeropositive womenAbsolute CD4Pregnant womenClinical trialsHIV-1Long-term effectsDaily food expenditureMalaria parasitesBaselineMonthsDar es SalaamCD4Food expenditure
2001
Do HIV Type 1 RNA Levels Provide Additional Prognostic Value to CD4+ T Lymphocyte Counts in Patients with Advanced HIV Type 1 Infection?
Arduino J, Fischl M, Stanley K, Collier A, Spiegelman D. Do HIV Type 1 RNA Levels Provide Additional Prognostic Value to CD4+ T Lymphocyte Counts in Patients with Advanced HIV Type 1 Infection? AIDS Research And Human Retroviruses 2001, 17: 1099-1105. PMID: 11522179, DOI: 10.1089/088922201316912709.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsHIV-1 disease progressionBaseline HIV-1 RNA levelsT-lymphocyte countsT lymphocytesDisease progressionLymphocyte countRNA levelsCells/Prognostic informationHigh baseline HIV-1 RNA levelsHIV type 1 RNA levelsPlasma HIV-1 RNA levelsSubsequent HIV-1 disease progressionAdvanced HIV-1 diseaseHIV Type 1 InfectionConditional logistic regression analysisDisease progression independentHIV-1 diseaseAdditional prognostic informationAdditional prognostic valueType 1 infectionCase-control studyLogistic regression analysisClinical statusPredictors of intrauterine and intrapartum transmission of HIV-1 among Tanzanian women
Fawzi W, Msamanga G, Renjifo B, Spiegelman D, Urassa E, Hashemi L, Antelman G, Essex M, Hunter D. Predictors of intrauterine and intrapartum transmission of HIV-1 among Tanzanian women. AIDS 2001, 15: 1157-1165. PMID: 11416718, DOI: 10.1097/00002030-200106150-00011.Peer-Reviewed Original ResearchConceptsViral loadHIV-1HIV-1-infected pregnant womenLower genital tract infectionMaternal CD4 cell countVertical transmissionLower genital infectionsMaternal viral loadCD4 cell countGenital tract infectionHIV disease progressionHIV-1 infectionWeeks of gestationPrevention of transmissionIntrapartum transmissionIntrauterine transmissionGenital infectionTract infectionsSustained clearanceClinical stagePregnant womenPrenatal careDisease progressionCopies/Vitamin supplements
1999
Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy
Shevitz A, Knox T, Spiegelman D, Roubenoff R, Gorbach S, Skolnik P. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS 1999, 13: 1351-1357. PMID: 10449288, DOI: 10.1097/00002030-199907300-00012.Peer-Reviewed Original ResearchConceptsFat-free massActive antiretroviral therapyHAART useHIV RNAAntiretroviral therapyCohort studyViral burdenKJ/dayHIV-seropositive menCD4 cell countHIV-seropositive personsLog10 copies/Energy expenditureLarge cohort studyIndependent effectsCross-sectional analysisHIV diseaseMedication regimensViral loadCopies/Adjusted REECell countElevated REEViral replicationHAART
1998
The effect of protease inhibitors on weight and body composition in HIV-infected patients
Silva M, Skolnik P, Gorbach S, Spiegelman D, Wilson I, Fernández-DiFranco M, Knox T. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998, 12: 1645-1651. PMID: 9764784, DOI: 10.1097/00002030-199813000-00012.Peer-Reviewed Original ResearchConceptsLean body massPI therapyHIV infectionWeight gainViral loadPhysical functioningHealth perceptionBody compositionCurrent health perceptionsActive antiretroviral therapyPI treatmentProtease inhibitor therapyBody mass indexGreater weight gainHuman growth hormoneAntiretroviral therapyHIV cohortBody massInhibitor therapyMass indexOptimal therapyFat massAnabolic stimuliPatientsGrowth hormonePredictors of level of circulating abnormal lymphocytes among human T‐lymphotropic virus type I carriers in Japan
Hisada M, Okayama A, Tachibana N, Stuver S, Spiegelman D, Tsubouchi H, Mueller N. Predictors of level of circulating abnormal lymphocytes among human T‐lymphotropic virus type I carriers in Japan. International Journal Of Cancer 1998, 77: 188-192. PMID: 9650550, DOI: 10.1002/(sici)1097-0215(19980717)77:2<188::aid-ijc3>3.0.co;2-m.Peer-Reviewed Original ResearchConceptsHuman T-lymphotropic virus type I carriersAdult T-cell leukemiaHigh proviral loadAbnormal lymphocytesProviral loadI carriersAsymptomatic HTLV-I carriersHTLV-I carriersT-cell leukemiaMale genderMultivariate analysisMalignant cellsBlood smearsPredictors of levelsLongitudinal studyLymphocytesPredictorsHTLVLeukemiaLevelsSmears